Saitama, Japan

Akiko Terauchi

This inventor holds 2 USPTO granted patents. Top assignee: Japan Science and Technology Agency. Active years: 2014-2015.


% Patents Active = 100.0

Average Co-Inventor Count = 7.5

ph-index = 1


Company Filing History:


Years Active: 2014-2015

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Akiko Terauchi: Innovator in Protein Crosslinking Inhibitors

Introduction

Akiko Terauchi is a notable inventor based in Saitama, Japan. She has made significant contributions to the field of biochemistry, particularly in the development of inhibitors for protein crosslinking. With a total of 2 patents, her work is paving the way for advancements in medical treatments.

Latest Patents

Terauchi's latest patents include innovative compounds that exhibit transglutaminase-inhibiting activity. One of her inventions relates to a ketone compound that can prevent or treat diseases caused by protein crosslinking. This compound is represented by specific chemical formulas, which include various substituted or unsubstituted aryl or heterocyclyl groups. Another patent focuses on a protein cross-linking inhibitor that contains a compound represented by multiple chemical structures, showcasing her expertise in this specialized area.

Career Highlights

Akiko Terauchi is affiliated with the Japan Science and Technology Agency, where she conducts her research and development. Her work is characterized by a strong focus on the biochemical mechanisms that underlie protein interactions and their implications for health.

Collaborations

Some of her notable coworkers include Etsuko Ebisui and Akinobu Suzuki, who contribute to her research endeavors. Their collaborative efforts enhance the scope and impact of her inventions.

Conclusion

Akiko Terauchi's innovative work in the field of protein crosslinking inhibitors exemplifies the importance of research in biochemistry. Her contributions are vital for the development of new therapeutic strategies.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…